Nasdaq Suffers Worst Month Since March 2025 as AI Costs and Fed Signals Pressure Tech
The Nasdaq endured its worst month since March 2025 as AI spending concerns and hawkish Fed commentary pressured technology stocks.
Marvell-Lumentum Deal Reportedly Set to Avoid Large Premium
A muted takeover premium could temper Lumentum shareholder enthusiasm and reshape merger-arbitrage e…
Acumen Pharmaceuticals Downgraded After Sabirnetug Fails Phase 2 Alzheimer’s Trial
Acumen’s ABOS faces a major biotech catalyst after sabirnetug missed key Phase 2 endpoints, promptin…
Regeneron Jumps 12% as Dupixent Royalties and Eylea HD Fuel Earnings Beat
Regeneron surged 12% after an earnings beat, powered by Dupixent royalties, Eylea HD sales, buybacks…
FDA Delays Mitapivat Sickle Cell Decision Until February 2027
The FDA extended its mitapivat review to February 2027, pushing a key regulatory and commercial cata…
Sun Pharma’s Ilumya Wins FDA Approval for Psoriatic Arthritis
FDA approval for Ilumya in active psoriatic arthritis broadens Sun Pharma’s U.S. immunology opportun…
NRx Pharmaceuticals Shares Jump 15% After Early FDA Approval for Preservative-Free Ketamine
NRx Pharmaceuticals won early FDA approval for preservative-free ketamine, sending NRXP shares appro…
Mineralys’ Positive CKD Data Expands the Investment Case for Lorundrostat
Positive Phase 2 CKD data may broaden lorundrostat’s commercial potential and sharpen investor inter…
SELLAS AML Trial Milestone Brings SLS Shares Closer to a High-Stakes Data Readout
SELLAS says its Phase 3 REGAL trial reached a statistical milestone, setting up preliminary topline …
Geron’s Imetelstat Myelofibrosis Trial Puts a Major Biotech Catalyst Back in Focus
Geron’s Phase 3 IMpactMF update places imetelstat at the center of a potentially binary catalyst for…